Baxalta now part of Shire
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Baxalta now part of Shire sits in the top decile of US sponsors by registered trial count (#294 of 15,742 sponsors by registered trial count).
Baxalta now part of Shire: 74 sponsored US clinical trials, 1 recruiting.
Baxalta now part of Shire sponsors 74 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 58 completed. 34 of these trials are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hemophilia A, with 4 trials.
Top-decile sponsor footprint
Baxalta now part of Shire ranks in the top decile of sponsors by registered trial count (#294 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
58 of 71 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
74 total, page 1 of 2
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
NCT02932618
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
NCT04158934
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
NCT01687608
A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants
NCT04578535
A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
NCT03879135
Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]
NCT03519672
A Study of BAX 888 in Male Adults With Severe Hemophilia A
NCT03370172
A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
NCT03393975
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
NCT03277313
Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia
NCT03185897
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
NCT02956122
Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews
NCT03054389
BAX 802 in CHA With Inhibitors
NCT02895945
Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice
NCT03199794
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
NCT02955355
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
NCT02722304
GAS-Hem Feasibility Study
NCT02674997
GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study
NCT02525861
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
NCT02610127
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT02549170
Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia
NCT02556775
BAX 855 PK-guided Dosing
NCT02585960
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
NCT02593188
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
NCT02615691
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
NCT02540356
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
NCT02448810
Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery
NCT02283268
BAX 855 Pediatric Study
NCT02210091
Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
NCT02216084
Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS
NCT02190149
Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
NCT01913405
BAX 855 Continuation
NCT01945593
Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen
NCT01757405
Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)
NCT01736475
Phase 2/3 Study of IGSC, 20% in PIDD
NCT01218438
Long-Term Study of IGIV, 10% in Alzheimer´s Disease
NCT01736579
GLASSIA Infusion Rate Study
NCT01651351
Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
NCT01765790
A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease
NCT01597401
Phase 3 IGIV, 10% in Alzheimer´s Disease
NCT01524887
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
NCT01485796
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
NCT01541670
Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)
NCT01410227
Osteoporosis and MRI Study in Hemophilia
NCT01460147
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A
NCT01434511
Early Prophylaxis Immunologic Challenge (EPIC) Study
NCT01376700
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
NCT01178294
Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID
NCT01175213
Ceprotin Treatment Registry
NCT01127529
Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor
NCT00851721
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 11 |
| Phase 3 | 29 |
| Phase 4 | 5 |
What is open in the Baxalta now part of Shire pipeline
1 recruiting of 74 indexed (1% open); 58 completed (78%).
Phase mix: 34 late (III/IV) vs 26 early (I/II) (balanced across stages).
Top condition: Hemophilia A (4 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Baxalta now part of Shire: open-pipeline peers nationwide
Peers matched on 74 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Baxalta now part of Shire sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 74 trials (± recruiting share)
- C. R. Bard · 75 trials · 5% recruiting
- ECOG-ACRIN Cancer Research Group · 75 trials · 16% recruiting
- Hartford Hospital · 75 trials · 11% recruiting
- Inova Health Care Services · 75 trials · 29% recruiting
Sponsors near 1% open enrollment (± trial volume)
- Astellas Pharma · 1% recruiting · 165 trials
- University of New Mexico · 1% recruiting · 168 trials
- Abbott Nutrition · 1% recruiting · 89 trials
- Power Life Sciences · 2% recruiting · 62 trials
Related
What to do with this Baxalta now part of Shire page
74 registered trials is a research-attention snapshot, not an endorsement of Baxalta now part of Shire or any single study.
- 1 of Baxalta now part of Shire's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hemophilia A is the condition Baxalta now part of Shire studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hemophilia A trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Baxalta now part of Shire pipeline card: 74 registered trials from official public datasets.Report a data error.